On June 3, GenScript Biotech surged 23.48% in regular trading, trading at HKD 14.6/share, with trading volume of HKD 156 million.

On the news front, GenScript's associate company Legend Biotech disclosed preliminary clinical data for its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy LB2501 in relapsed or refractory B-cell non-Hodgkin's lymphoma (R/R B-NHL) patients, showing positive signals. The data will be presented at the European Hematology Association (EHA) annual meeting to be held in Stockholm, Sweden from June 11 to June 14. By generating CAR-T cells directly within the patient's body, this approach has the potential to simplify the treatment process and improve accessibility for patients who are difficult to cover with traditional CAR-T cell therapies.

This follows closely on the heels of Legend Biotech's ASCO presentations featuring LB2102 first-in-human data targeting DLL3 for solid tumors and updated CARVYKTI data for multiple myeloma. The successive pipeline catalysts, combined with ongoing market discussion around GenScript's valuation discount relative to its Legend Biotech stake, have collectively driven strong upward momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)